Collateral Ventilation

Recent research suggests that collateral ventilation can limit the effectiveness of lung-volume reduction therapy for severe emphysema.^1,2 Pulmonx’ Chartis System can identify the presence of collateral ventilation in the lungs. This may enable physicians to better identify patients who could benefit from Endobronchial Valve therapy.

Data-driven treatment planning

The combination of the Chartis System and Endobronchial Valve therapy offers severe emphysema patients a promising option for endobronchial lung volume reduction. Pulmonx’ unique approach to emphysema is intended to provide physicians and patients with physiologic information to guide treatment decisions.

Footnotes:

1. Aljuri N, Freitag L. Validation and pilot clinical study of a new bronchoscopic method to measure collateral ventilation prior to endobronchial lung volume reduction. J Appl Physiol. 2009;106:774-783.

2. Fessler HE. Collateral damage assessment for endobronchial lung volume reduction. J Appl Physiol. 2009;106:755-756.

*Investigational device in the United States. Limited by law to investigational use.